All In Biotech

Drug Trial Radar · NCT04660539

A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)

A Multicenter, Single Arm, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Last checked: Nov 20, 2026Latest source record: Dec 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

119

Actual

Start

Mar 2, 2021

Primary completion

May 28, 2024

Study completion May 28, 2024

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Dec 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This multicenter, single-arm, open-label study will evaluate the long-term safety and efficacy of satralizumab in participants with neuromyelitis optica spectrum disorder (NMOSD) who completed open-label extension (OLE) period of studies BN40898 and BN40900. Participants will receive satralizumab as monotherapy or in combination with one of the following background immunosuppressive treatments: azathioprine (AZA), mycophenolate mofetil (MMF), or oral corticosteroids.

Conditions

  • Neuromyelitis Optica Spectrum Disorder

Interventions

  • satralizumabDrug

    Satralizumab will be administered by SC injection in the abdominal or femoral region at a dose of 120 mg (fixed dose) Q4W for up to 3 years

  • azathioprine (AZA)Drug

    Participants are permitted to use AZA during the study as background immunosuppressive treatment at a maximum dose of 3 milligram per kilogram per day (mg/kg/day)

  • mycophenolate mofetil (MMF)Drug

    Participants are permitted to use MMF during the study as background immunosuppressive treatment at a maximum dose of 3000 mg/day

  • oral corticosteroidsDrug

    Participants are permitted to use oral corticosteroids (prednisolone equivalent) during the study as background immunosuppressive treatment at a maximum dose of 15 mg/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Baseline up to 523 weeks
  2. Number of Participants With Adverse Events of Special Interest (AESIs) and Selected AEsTime frame: Baseline up to 523 weeks

Locations

53 sites in 18 countries. Site status is shown where the registry gives one.

  • Children's Hospital of Alabama

    Birmingham, Alabama

  • University of Miami

    Miami, Florida

  • Columbus Research and Wellness

    Columbus, Georgia

  • University of Chicago

    Chicago, Illinois

  • Consultants in Neurology Ltd

    Northbrook, Illinois

  • OSF Saint Francis Medical Center

    Peoria, Illinois

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Wayne State University; UHC-4H

    Detroit, Michigan

  • The Neurological Institute PA

    Charlotte, North Carolina

  • OhioHealth Research Institute

    Columbus, Ohio

  • Jefferson Hospital For Neuroscience; Jefferson Neurology Associates

    Philadelphia, Pennsylvania

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Central Texas Neurology Consultants

    Round Rock, Texas

  • UMHAT 'Dr. Georgi Stranski', EAD

    Pleven, Bulgaria

  • Multiprofile Hospital for Active Treatment of Neurology and Psychiatry Sv. Naum EAD

    Sofia, Bulgaria

  • University Multiprofile Hospital for Active Treatment Aleksandrovska EAD

    Sofia, Bulgaria

  • MS Clinical Trials Group

    Vancouver, British Columbia, Canada

  • Centre hospitalier de l'Universite de Montreal (CHUM)

    Montreal, Quebec, Canada

  • Clinical Hospital Centre Osijek

    Osijek, Croatia

  • Ruhr Universitat Bochum

    Bochum, Germany

  • Jahn Ferenc Del-Pesti Korhaz es Rendelointezet

    Budapest, Hungary

  • Azienda Ospedaliera Sant'Andrea

    Rome, Lazio, Italy

  • Azienda Ospedaliero Universitaria Policlinico Vittorio Emanuele

    Catania, Sicily, Italy

  • Kyushu University Hospital

    Fukuoka, Japan

  • Tohoku University Hospital

    Miyagi, Japan

  • Niigata University Medical & Dental Hospital

    Niigata, Japan

  • Osaka University Hospital

    Osaka, Japan

  • Kindai University Hospital

    Osaka, Japan

  • Tokyo Women's Medical University Hospital

    Tokyo, Japan

  • National Center of Neurology and Psychiatry

    Tokyo, Japan

  • Hospital Kuala Lumpur

    Kuala Lumpur, FED. Territory of Kuala Lumpur, Malaysia

  • NZOZ Wielospecjalistyczna Poradnia Lekarska SYNAPSIS

    Katowice, Poland

  • M.A. - LEK A. M. Maciejowscy SC. Centrum Terapii SM

    Katowice, Poland

  • Samodzielny Publiczny Szpital Kliniczny Nr 4 w Lublinie; Klinika Neurologii

    Lublin, Poland

  • Uniwersyteckie Centrum Kliniczne WUM, Centralny Szpital Kliniczny; Klinika Neurologii

    Warsaw, Poland

  • Instytut Psychiatrii i Neurologii

    Warsaw, Poland

  • Miedzyleski Szpital Specjalistyczny w Warszawie

    Warsaw, Poland

  • San Juan MS Center

    Guaynabo, Puerto Rico

  • SC Clubul Sanatatii SRL

    Campulung Muscel, Romania

  • Korea University Anam Hospital

    Seoul, South Korea

Showing 40 of 53 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.